Alta Partners
Venture capitalJackson · Seed–Growth · 9 people tracked
Also known as ALTA PARTNERS INVESTMENT MANAGER, L.P. · ALTA PARTNERS MANAGEMENT COMPANY, L.P. · Alta Partners NextGen
Investment thesis
Alta Partners believes the healthcare sector has reached an inflection point where technology and innovation enable greater integration among physicians, payers, and patients to deliver better outcomes. The firm holds that healthcare should ultimately serve patients, and it is dedicated to supporting entrepreneurs in building high-impact companies. Its portfolio and outcomes center on life sciences and biotechnology, including cell and gene therapies, precision medicines, and clinical-stage biopharmaceutical companies.
Source: firm website, verified Aug 3, 2026.
Team · 9 people
from the firm's website & public directories
What they invest in
from 22 of 66 portfolio companiesBiotech ×13Healthtech ×11Medical Devices ×5Deep Tech ×2Digital Health ×2SaaS ×2AI & Machine Learning ×1B2B Marketplaces ×1
HQs:United States×24
Investments · 66 tracked
founders shown can be your intro pathBiotechPittsburgh, US
Doug Norby(Director)Dan Janney(Director)Dino Rossi(Director)Suma M. Krishnan(Director)Krish S. Krishnan(Executive Officer, Director)
Board seatDan Janney· per SEC Form D · $11.3M raise · filed Aug 2017
Received FDA 510(k) clearance for its StimRouter pain management device and SonaStar Elite.
HealthtechAndover, US
Edwin M. Kania, Jr.(Director)Waleed H. Hassanein(Executive Officer, Director)James R. Tobin(Director)Kenneth Bate(Director)David Abrams(Director)Joseph S. Lacob(Director)
BiotechCarlsbad, US
Robert More(Director)Hiroomi Tada, M.D., Ph.D.(Executive Officer)Isan Chen, M.D.(Director)Daniel Bensen(Executive Officer)Nina Kjellson(Director)Alan Fuhrman(Executive Officer)
San Francisco, US
BiotechSan Carlos, US
Nenad Tomasevic(Executive Officer)Farah Champsi(Director)Alejandro Dorenbaum(Executive Officer)Peter Moldt(Director)Christopher Bebbington(Executive Officer, Director)
BoardJohn McKearn(Director)
Board seatDan JanneyFarah Champsi· per SEC Form D
Berkeley, US
Peter Calthorpe(Executive Officer, Director)
Board seatGarrett Gruener· per SEC Form D · $2M raise · filed Jul 2019
HealthtechPalo Alto, US
DAVID CLAPPER(Director)ALBERT CHA(Director)EDWARD W. UNKART(Director)GUY P. NOHRA(Director)MARCEE M. MARONEY(Executive Officer)DAVID GRAVETT(Executive Officer)
Board seatGuy Nohra· per SEC Form D · $4M raise · filed Mar 2015
Cambridge, US
Board seatBob More· per SEC Form D · $50.3M raise · filed Apr 2022
Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells.
BiotechDeep TechMedical DevicesWatertown, US
Aleks Radovic-Moreno(Director)Dmitrij Hristodorov(Director)Dan Janney(Director)Christopher Loose(Executive Officer, Director)Cassidy Blundell(Director)Sanjay Magavi(Executive Officer)
Board seatDan Janney· per SEC Form D
Prolacta Bioscience manufactures 100% human milk-based nutritional products and fortifiers for premature and critically ill infants in hospital neonatal intensive care units.
BiotechHealthtechMedical DevicesCity Of Industry, US
Scott Elster(Executive Officer, Director)Frank Foster(Director)Martin Sutter(Director)John Bacich, Jr.(Director)Ernie Strapazon(Director)Ned Brown(Director)
Board seatDan Janney· per SEC Form D
BiotechHealthtechSouth San Francisco, US
WARREN THALER(Director)Eugene de Juan(Executive Officer, Director)ANTHONY ADAMIS(Director)FREDERIC GUERARD(Director)JEAN-FREDERIC PAULSEN(Director)Guy Jean Savoir Garcia(Director)
Board seatGuy Nohra· per SEC Form D · $10.9M raise · filed Feb 2023
HealthtechSan Clemente, US
Mike Chuisano(Director)Tracy Maahs(Executive Officer)Scott Moonly(Executive Officer, Director)George Abi-Chahine(Director)John Cox(Executive Officer)Guy Nohra(Director)
Board seatGuy Nohra· per SEC Form D · $4M raise · filed Jun 2019
Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.
BiotechHealthtechMedical Devices
Portfolio company that completed a successful 2018 biotech IPO, resulting in a 9x return for RiverVest.
PartnerDan Janney· led
BiotechCambridge, US
Tina Liu(Executive Officer, Director)David Cordo(Executive Officer)Erica Whittaker(Director)Steve Gillis(Director)
BoardBob More(Director)
Ark provides a customizable digital platform for venture capital and private equity firms to manage investor communications, performance reporting, and document sharing with their limited partners.
Enterprise SoftwareFintechSaaS
Boston, US
Dan Adams(Executive Officer, Director)
BoardPete Hudson(Director)Bruce Herzfelder(Director)Mark Prather(Director)
Therapeutics company acquired by MedImmune.
Received FDA approval for TEMBEXA (brincidofovir) to treat smallpox.
Received FDA approval for Tracleer to treat pulmonary arterial hypertension.
PartnerDan Janney· led
BiotechSan Carlos, US
Anthony P. Ford(Executive Officer, Director)Benjamin Potter(Executive Officer)Henry Skinner(Director)Liam Ratcliffe(Director)
BoardRon Hunt(Director)Loretta Tse, Ph.D.(Director)
Received FDA approvals for the enlighten and Secret RF microneedling systems for skin conditions.
DispatchHealth delivers in-home medical care and house call services, offering patients an alternative to emergency rooms and urgent care facilities for acute medical conditions.
Digital HealthHealthtech
Dr. Mark Prather(Founder)Kevin Riddleberger(Founder)Dominic Bagnoli(Director)Pete Hudson(Director)
eGenesis uses gene editing and genome engineering to develop porcine donor animals for cross-species organ transplantation, addressing organ failure treatment and transplant supply constraints.
BiotechDeep TechMedical Devices
Mike Curtis, Ph.D.(President & Chief Executive Officer)
BiotechBrookline, US
Luhan Yang(President, Secretary and Treasurer)George M. Church(Director)Geoff MacKay(Chief Executive Officer)
PartnerDan Janney· led
Received FDA approvals for Vazculep and Akovaz to treat anesthesia-related hypotension.
Received FDA approval for Vyndamax and Vyndaqel to treat ATTR-CM cardiomyopathy.
Free Market Health operates a care-driven marketplace platform for the specialty pharmacy ecosystem.
B2B MarketplacesHealthtechSaaSPittsburgh, US
Harbor Health is a healthcare provider and insurance company operating clinics across Texas that offers primary care, specialty care, and health coaching alongside integrated insurance coverage.
HealthtechInsurTechAustin, US
Pete Hudson(Director)Anthony Miller(Director)Sterling Claiborne Johnston(Chief Medical Officer)Jeffrey Fisher(Chief Financial Officer)Sebastian Caliri(Director)Brian Beutner(Corporate Secretary)
Oncology company that received FDA approval for Campath to treat B-cell chronic lymphocytic leukemia.
PartnerDan Janney· led
Pharma company acquired by Roche; received FDA approval for Esbriet to treat idiopathic pulmonary fibrosis.
Developing in vivo CAR-T cell therapies for cancer treatment
Biosciences company acquired by Bristol-Myers Squibb.
Daly City, US
Elizabeth Stanley(Director)Weston Whitaker(Executive Officer, Director, Promoter)Samuel Smits(Director)William DeLoache(Director)
HealthtechCambridge, US
Philippe Amouyal(Director)Jonathan White(Director)Justin Barstein(Director)Martin Coulter(Executive Officer, Director)Jay M. Tenenbaum(Director)James Heywood(Director)
Received FDA approval for Elocta to treat Hemophilia A.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Fund performance · per public LP disclosures · 7
as of Sep 2024| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Alta Partners VIIILPs: Employees' Retirement System of Rhode Island, Hawaii Employees' Retirement System | 2006 | — | 16.3% | 2.47x | 2.47x |
| Alta BioPharma Partners IIILPs: Employees' Retirement System of Rhode Island | 2003 | — | 5.8% | 1.50x | 1.42x |
| Alta BioPharma Partners II, L.P.LPs: California Public Employees' Retirement System | 2000 | — | 3.2% | 1.18x | 0.96x |
| Alta Subordinated Debt Partners IIILPs: The Regents of the University of California | 1993 | — | 28.8% | 3.40x | 3.40x |
| Alta Subordinated Debt Partners IILPs: The Regents of the University of California | 1988 | — | 12.1% | 2.12x | 2.12x |
| Alta Subordinated Debt PartnersLPs: The Regents of the University of California | 1986 | — | 8.6% | 1.88x | 1.88x |
| Alta Co PartnersLPs: The Regents of the University of California | 1980 | — | 13.6% | 2.22x | 2.22x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- What stage does Alta Partners invest at?
- Alta Partners invests at the Seed, Series A, Series B, Series C, Growth stages.
- What is Alta Partners's typical check size?
- Alta Partners typically writes checks of $1M – $12M.
- What sectors does Alta Partners focus on?
- Alta Partners focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Alta Partners located?
- Alta Partners is headquartered in Jackson, US.
Media · Podcasts & interviews
featuring the teamPete Hudson, Alta Partners & Transcarent Investor, Part 1
The Health Care Blog's Channel · Pete Hudson
Images
Co-investors · 17
Longwood Fund is a Boston-based venture firm focused on discovering and building science-based companies, with a team spanning doctors, scientists, entrepreneurs, and investors.
General Catalyst is a venture capital and investment firm that backs founders across industries, with a strong focus on AI-driven transformation, fintech, healthcare, and other sectors.
Canaan is an early-stage venture capital firm backing founders with transformative ideas across technology and healthcare.
Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.
Questa Capital is a venture capital firm that partners with teams building next-generation healthcare companies focused on improving patient outcomes and reducing costs.
RiverVest Venture Partners is a life sciences venture capital firm that invests in biotechnology and medical companies, working with entrepreneurs to advance therapeutic and medical innovations.
Astellas Venture Management (AVM) is the wholly-owned corporate venture arm of Astellas, providing equity investments to private, early-stage biotechnology companies developing therapeutic programs and platform technologies for drug discovery.
Insight Partners is a venture and growth-stage software investor featuring a large portfolio of technology companies across multiple sectors and regions.
Unknown is an investment firm focused on emerging market opportunities in live entertainment, biosciences, technology startups, and real estate, with a portfolio spanning music festivals, artist platforms, creator financial services, and event infrastructure.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
S32 is a high-conviction venture firm that concentrates on a small set of core relationships, committing deeply and supporting founders over the long term.
▶5 more co-investors
Forbion5AM VenturesDomain AssociatesAsset Management VenturesFrazier Healthcare Partners
Firms observed investing alongside Alta Partners, from public investor directories. Shared companies are the overlap with Alta Partners's recorded portfolio.
Similar investors
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.
Averin Capital is an investment firm focused on the intersection of technology and health, backing teams building companies in areas such as early disease detection, treatment delivery, personalized care, and medical breakthroughs.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Lumira Ventures is a North American life sciences venture capital firm that partners with mission-driven entrepreneurs to build companies developing and commercializing healthcare products for patients.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.